(S)-3-methyl-2-phenylbutyramide | 174290-51-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-3-methyl-2-phenylbutyramide
• 英文别名: (2S)-3-methyl-2-phenylbutanamide
• CAS: 174290-51-8
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: TZWZKDIRNLJDQG-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-3-methyl-2-phenylbutyramide 在 劳森试剂 、 吡啶 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 24.03h， 生成
  参考文献：
  名称：

  Synthesis of chiral disulfides: potential reagents for enantioselective sulfurization

  摘要：

  Synthesis of chiral phosphorothioates for use as antisense oligonucleotides might benefit from the use of chiral disulfides. This paper reports the synthesis of chiral analogs of phenylacetyl disulfide and of 5-methyl-3H-1,2,4-dithiazol-3-one from the same set of 2-arylalkanoic acids. The X-ray crystal structures of the disulfides derived from (R) and [S]-2-phenylpropanoic acid establish the stereochemistry and the helicity of these materials, and density functional theory calculations suggest that the high specific rotations can be due to preferred retention of this helicity in solution. Chiral HPLC showed that the final products were formed with enantiomeric purities from 86.1% to99.9%. [image omitted].

  DOI：

  10.1080/17415993.2011.580346
• 作为产物：
  描述：

  (alphaS)-alpha-(1-甲基乙基)苯乙酸 在 氯化亚砜 、 ammonium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 20.0h， 以95%的产率得到(S)-3-methyl-2-phenylbutyramide
  参考文献：
  名称：

  探索3-甲基-2-苯基丁酰胺的晶体景观：从稳定的团块中亚稳的外消旋形式的结晶

  摘要：

  在固态下，（±）-3-甲基-2-苯基丁酰胺1自发地分解为团聚体（形式I），该团聚体在熔融后结晶为外消旋形式（形式II），随后发生气相结晶，这是很少报道的现象。表征了另一种外消旋多晶型物形式III，并通过多种计算和实验方法（包括研磨，浆液结晶和晶种技术）建立了这三种形式之间的热力学关系。外消旋形式II和III是亚稳和容易地转换为更稳定的砾岩，的不同多晶型物的晶型I的密度泛函理论计算1所表明的对映异构体1（- [R ＆小号）比两种外消旋形式都更稳定。

  DOI：

  10.1021/acs.cgd.8b00348

文献信息

• [EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012125887A1

  公开（公告）日：2012-09-20

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  揭示了式（I）的化合物及其药用盐。式（I）的化合物抑制JAK3的酪氨酸激酶活性，因此它们可用于治疗炎症和自身免疫性疾病。
• BENZIMIDAZOLONE DERIVATIVES
  申请人：Ando Kazuo

  公开号：US20090298811A1

  公开（公告）日：2009-12-03

  This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R 1 , R 2 and R 3 are each as described herein. These compounds are useful in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, spasticity, epilepsy, Tourette's syndrome, Parkinson's disease, neuroprotection, anxiety, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, cachexia, nausea, emesis, chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasodialation, hypertension, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis and bronchitis.

  本发明涉及化合物和方法，用于治疗由CB1受体活性在哺乳动物主体中介导的疾病，包括人类，其包括向需要该治疗的哺乳动物施用化合物的治疗有效量的公式(I)或其药用可接受盐，其中：A、B、R1、R2和R3如本文所述。这些化合物在治疗由CB2受体结合活性介导的疾病中有用，如但不限于炎症性疼痛、伤害性疼痛、神经性疼痛、纤维肌痛、慢性腰痛、内脏疼痛、急性脑缺血、疼痛、慢性疼痛、急性疼痛、带状疱疹后神经痛、神经病、神经痛、糖尿病性神经病、艾滋病相关神经病、神经损伤、类风湿性关节炎疼痛、骨关节炎疼痛、背部疼痛、癌症疼痛、牙痛、纤维肌痛、神经炎、坐骨神经痛、炎症、神经退行性疾病、痉挛、癫痫、托瑞特综合征、帕金森病、神经保护、焦虑、咳嗽、支气管痉挛、肠易激综合征（IBS）、炎症性肠病（IBD）、结肠炎、脑血管缺血、虚弱、恶心、呕吐、化疗诱导呕吐、类风湿关节炎、哮喘、克罗恩病、溃疡性结肠炎、皮炎、季节性过敏性鼻炎、胃食管反流病（GERD）、便秘、腹泻、功能性胃肠障碍、皮肤T细胞淋巴瘤、多发性硬化症、骨关节炎、牛皮癣、系统性红斑狼疮、糖尿病、青光眼、骨质疏松症、肾小球肾炎、肾缺血、肾炎、肝炎、脑中风、血管扩张、高血压、血管炎、心肌梗死、脑缺血、可逆气道阻塞、成人呼吸系统疾病综合征、慢性阻塞性肺疾病（COPD）、隐源性纤维化肺泡炎和支气管炎。
• [EN] QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE QUINOLEINE 4-CARBOXAMIDE ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE LA NEUROKININE 3 (NK-3)
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005014575A1

  公开（公告）日：2005-02-17

  The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).

  该发明涉及新型喹啉衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途，特别是在治疗中枢神经系统（CNS）疾病方面的用途。
• Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists
  申请人：Chan Ngor Wai

  公开号：US20070142431A1

  公开（公告）日：2007-06-21

  The invention relates to novel quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).

  本发明涉及新的喹啉衍生物、其制备方法、含有它们的制药组合物以及它们作为药物的用途，特别是用于治疗中枢神经系统（CNS）疾病。
• INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20140336440A1

  公开（公告）日：2014-11-13

  Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed.

  本文揭示了具有抑制Rho相关蛋白激酶（ROCKs）活性的化合物和组合物，以及制备和使用这些化合物的方法。